Progress in the treatment of Alzheimer’s disease is needed: position statement of European Alzheimer’s Disease Consortium (EADC) Investigators
β-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer’s disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall va...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 2024
|
| In: |
The journal of prevention of Alzheimer's disease
Year: 2024, Jahrgang: 11, Heft: 5, Pages: 1212-1218 |
| ISSN: | 2426-0266 |
| DOI: | 10.14283/jpad.2024.153 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.14283/jpad.2024.153
|
| Verfasserangaben: | Frank Jessen, M.G. Kramberger, D. Angioni, D. Aarsland, M. Balasa, K. Bennys, M. Boada, M. Boban, A. Chincarini, L. Exalto, A. Felbecker, K. Fliessbach, G.B. Frisoni, A.J. Garza-Martínez, T. Grimmer, B. Hanseeuw, J. Hort, A. Ivanoiu, S. Klöppel, L. Krajcovicova, B. McGuinness, P. Mecocci, A. de Mendonca, A. Nous, P.-J. Ousset, C. Paquet, R. Perneczky, O. Peters, M. Tabuas-Pereira, F. Piazza, D. Plantone, M. Riverol, A. Ruiz, G. Sacco, I. Santana, N. Scarmeas, E. Solje, E. Stefanova, S. Sutovsky, W. van der Flier, T. Welsh, A. Wimo, B. Winblad, L. Frölich, S. Engelborghs |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1907481028 | ||
| 003 | DE-627 | ||
| 005 | 20241205184230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241104s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14283/jpad.2024.153 |2 doi | |
| 035 | |a (DE-627)1907481028 | ||
| 035 | |a (DE-599)KXP1907481028 | ||
| 035 | |a (OCoLC)1475637150 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 11 |2 sdnb | ||
| 100 | 1 | |a Jessen, Frank |d 1967- |e VerfasserIn |0 (DE-588)12077447X |0 (DE-627)080880762 |0 (DE-576)292379285 |4 aut | |
| 245 | 1 | 0 | |a Progress in the treatment of Alzheimer’s disease is needed |b position statement of European Alzheimer’s Disease Consortium (EADC) Investigators |c Frank Jessen, M.G. Kramberger, D. Angioni, D. Aarsland, M. Balasa, K. Bennys, M. Boada, M. Boban, A. Chincarini, L. Exalto, A. Felbecker, K. Fliessbach, G.B. Frisoni, A.J. Garza-Martínez, T. Grimmer, B. Hanseeuw, J. Hort, A. Ivanoiu, S. Klöppel, L. Krajcovicova, B. McGuinness, P. Mecocci, A. de Mendonca, A. Nous, P.-J. Ousset, C. Paquet, R. Perneczky, O. Peters, M. Tabuas-Pereira, F. Piazza, D. Plantone, M. Riverol, A. Ruiz, G. Sacco, I. Santana, N. Scarmeas, E. Solje, E. Stefanova, S. Sutovsky, W. van der Flier, T. Welsh, A. Wimo, B. Winblad, L. Frölich, S. Engelborghs |
| 264 | 1 | |c October 2024 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 11. August 2024 | ||
| 500 | |a Gesehen am 04.11.2024 | ||
| 520 | |a β-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer’s disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall value. In this position statement academic clinicians of the European Alzheimer’s Disease Consortium (EADC) discuss the critical relevance of introducing these new treatments in clinical care now. Given the complexity of AD it is unlikely that molecular single-target treatments will achieve substantially larger effects than those seen with current β-amyloid-targeting antibodies. Larger effects will most likely only be achieved incrementally by continuous optimization of molecular approaches, patient selection and combinations therapies. To be successful in this regard, drug development must be informed by the use of innovative treatments in real world practice, because full understanding of all facets of novel treatments requires experience and data of real-world care beyond those of clinical trials. Regarding the antibodies under discussion we consider their effects meaningful and potential side effects manageable. We assume that the number of eventually treated patient will only be a fraction of all early AD patients due to narrow eligibility criteria and barriers of access. We strongly endorse the use of these new compound in clinical practice in selected patients with treatment documentation in registries. We understand this as a critical step in advancing the field of AD treatment, and in shaping the health care systems for the new area of molecular-targeted treatment of neurodegenerative diseases. | ||
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a amyloid imaging related abnormalities | |
| 650 | 4 | |a disease modifying treatment | |
| 650 | 4 | |a mild cognitive impairment | |
| 650 | 4 | |a β-amyloid-targeting treatment | |
| 700 | 1 | |a Kramberger, M. G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Angioni, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aarsland, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Balasa, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bennys, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boada, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boban, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chincarini, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Exalto, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Felbecker, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fliessbach, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frisoni, G. B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garza-Martínez, A. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grimmer, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hanseeuw, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hort, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ivanoiu, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klöppel, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krajcovicova, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a McGuinness, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mecocci, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Mendonca, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nous, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ousset, P.-J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paquet, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perneczky, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peters, O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tabuas-Pereira, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Piazza, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Plantone, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Riverol, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ruiz, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sacco, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Santana, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scarmeas, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Solje, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stefanova, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sutovsky, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a van der Flier, W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Welsh, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wimo, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Winblad, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frölich, Lutz |d 1956- |e VerfasserIn |0 (DE-588)1028327099 |0 (DE-627)730567516 |0 (DE-576)375813160 |4 aut | |
| 700 | 1 | |a Engelborghs, S. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of prevention of Alzheimer's disease |d [Paris] : Elsevier Masson SAS, 2014 |g 11(2024), 5 vom: Okt., Seite 1212-1218 |h Online-Ressource |w (DE-627)795124716 |w (DE-600)2782183-3 |w (DE-576)411990772 |x 2426-0266 |7 nnas |a Progress in the treatment of Alzheimer’s disease is needed position statement of European Alzheimer’s Disease Consortium (EADC) Investigators |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:5 |g month:10 |g pages:1212-1218 |g extent:7 |a Progress in the treatment of Alzheimer’s disease is needed position statement of European Alzheimer’s Disease Consortium (EADC) Investigators |
| 856 | 4 | 0 | |u https://doi.org/10.14283/jpad.2024.153 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241104 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1028327099 |a Frölich, Lutz |m 1028327099:Frölich, Lutz |d 60000 |e 60000PF1028327099 |k 0/60000/ |p 44 | ||
| 999 | |a KXP-PPN1907481028 |e 4609816520 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"given":"Frank","role":"aut","display":"Jessen, Frank","family":"Jessen"},{"role":"aut","given":"M. G.","family":"Kramberger","display":"Kramberger, M. G."},{"display":"Angioni, D.","family":"Angioni","given":"D.","role":"aut"},{"role":"aut","given":"D.","display":"Aarsland, D.","family":"Aarsland"},{"family":"Balasa","display":"Balasa, M.","role":"aut","given":"M."},{"display":"Bennys, K.","family":"Bennys","role":"aut","given":"K."},{"display":"Boada, M.","family":"Boada","role":"aut","given":"M."},{"role":"aut","given":"M.","family":"Boban","display":"Boban, M."},{"family":"Chincarini","display":"Chincarini, A.","given":"A.","role":"aut"},{"family":"Exalto","display":"Exalto, L.","given":"L.","role":"aut"},{"family":"Felbecker","display":"Felbecker, A.","role":"aut","given":"A."},{"display":"Fliessbach, K.","family":"Fliessbach","role":"aut","given":"K."},{"display":"Frisoni, G. B.","family":"Frisoni","given":"G. B.","role":"aut"},{"family":"Garza-Martínez","display":"Garza-Martínez, A. J.","given":"A. J.","role":"aut"},{"display":"Grimmer, T.","family":"Grimmer","given":"T.","role":"aut"},{"role":"aut","given":"B.","display":"Hanseeuw, B.","family":"Hanseeuw"},{"given":"J.","role":"aut","family":"Hort","display":"Hort, J."},{"given":"A.","role":"aut","display":"Ivanoiu, A.","family":"Ivanoiu"},{"display":"Klöppel, S.","family":"Klöppel","given":"S.","role":"aut"},{"family":"Krajcovicova","display":"Krajcovicova, L.","role":"aut","given":"L."},{"role":"aut","given":"B.","family":"McGuinness","display":"McGuinness, B."},{"given":"P.","role":"aut","display":"Mecocci, P.","family":"Mecocci"},{"role":"aut","given":"A.","family":"de Mendonca","display":"de Mendonca, A."},{"display":"Nous, A.","family":"Nous","role":"aut","given":"A."},{"role":"aut","given":"P.-J.","family":"Ousset","display":"Ousset, P.-J."},{"role":"aut","given":"C.","display":"Paquet, C.","family":"Paquet"},{"role":"aut","given":"R.","family":"Perneczky","display":"Perneczky, R."},{"role":"aut","given":"O.","display":"Peters, O.","family":"Peters"},{"role":"aut","given":"M.","display":"Tabuas-Pereira, M.","family":"Tabuas-Pereira"},{"family":"Piazza","display":"Piazza, F.","role":"aut","given":"F."},{"family":"Plantone","display":"Plantone, D.","role":"aut","given":"D."},{"role":"aut","given":"M.","family":"Riverol","display":"Riverol, M."},{"display":"Ruiz, A.","family":"Ruiz","given":"A.","role":"aut"},{"role":"aut","given":"G.","family":"Sacco","display":"Sacco, G."},{"family":"Santana","display":"Santana, I.","role":"aut","given":"I."},{"family":"Scarmeas","display":"Scarmeas, N.","given":"N.","role":"aut"},{"family":"Solje","display":"Solje, E.","given":"E.","role":"aut"},{"role":"aut","given":"E.","family":"Stefanova","display":"Stefanova, E."},{"role":"aut","given":"S.","family":"Sutovsky","display":"Sutovsky, S."},{"role":"aut","given":"W.","display":"van der Flier, W.","family":"van der Flier"},{"display":"Welsh, T.","family":"Welsh","role":"aut","given":"T."},{"role":"aut","given":"A.","family":"Wimo","display":"Wimo, A."},{"family":"Winblad","display":"Winblad, B.","role":"aut","given":"B."},{"family":"Frölich","display":"Frölich, Lutz","role":"aut","given":"Lutz"},{"role":"aut","given":"S.","display":"Engelborghs, S.","family":"Engelborghs"}],"id":{"doi":["10.14283/jpad.2024.153"],"eki":["1907481028"]},"name":{"displayForm":["Frank Jessen, M.G. Kramberger, D. Angioni, D. Aarsland, M. Balasa, K. Bennys, M. Boada, M. Boban, A. Chincarini, L. Exalto, A. Felbecker, K. Fliessbach, G.B. Frisoni, A.J. Garza-Martínez, T. Grimmer, B. Hanseeuw, J. Hort, A. Ivanoiu, S. Klöppel, L. Krajcovicova, B. McGuinness, P. Mecocci, A. de Mendonca, A. Nous, P.-J. Ousset, C. Paquet, R. Perneczky, O. Peters, M. Tabuas-Pereira, F. Piazza, D. Plantone, M. Riverol, A. Ruiz, G. Sacco, I. Santana, N. Scarmeas, E. Solje, E. Stefanova, S. Sutovsky, W. van der Flier, T. Welsh, A. Wimo, B. Winblad, L. Frölich, S. Engelborghs"]},"physDesc":[{"extent":"7 S."}],"recId":"1907481028","relHost":[{"language":["eng"],"part":{"year":"2024","pages":"1212-1218","text":"11(2024), 5 vom: Okt., Seite 1212-1218","issue":"5","extent":"7","volume":"11"},"recId":"795124716","physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["Clinical Trials on Alzheimer's Disease (CTAD) ; International Association of Gerontology and Geriatrics (IAGG)"]},"id":{"issn":["2426-0266"],"zdb":["2782183-3"],"eki":["795124716"]},"title":[{"subtitle":"JPAD","title_sort":"journal of prevention of Alzheimer's disease","title":"The journal of prevention of Alzheimer's disease"}],"pubHistory":["1.2014 -"],"note":["Gesehen am 04.02.25"],"origin":[{"publisher":"Elsevier Masson SAS ; SERDI ; Springer International Publishing","dateIssuedKey":"2025","dateIssuedDisp":"2025-","publisherPlace":"[Paris] ; Toulouse ; Cham"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Progress in the treatment of Alzheimer’s disease is needed position statement of European Alzheimer’s Disease Consortium (EADC) InvestigatorsThe journal of prevention of Alzheimer's disease"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"October 2024","dateIssuedKey":"2024"}],"note":["Online veröffentlicht: 11. August 2024","Gesehen am 04.11.2024"],"title":[{"title":"Progress in the treatment of Alzheimer’s disease is needed","subtitle":"position statement of European Alzheimer’s Disease Consortium (EADC) Investigators","title_sort":"Progress in the treatment of Alzheimer’s disease is needed"}]} | ||
| SRT | |a JESSENFRANPROGRESSIN2024 | ||